FDA’s Updated Biosimilar Policy: What it really means in the US, EU5, Japan, and China
The regulatory landscape for biosimilars is shifting significantly in 2025. The FDA has taken two big steps that collectively make it faster and cheaper to bring many biosimilars to market: In June 2024, the FDA proposed to drop “switching” studies for the interchangeable designation, saying most products won’t need extra human trials just to prove patients can switch back and forth. In October 2025, the FDA issued new draft guidance signaling that comparative efficacy trials may often be unnecessary for showing biosimilarity, putting more weight on analytics, PK/PD, and totality of evidence. The FDA also previewed steps to make interchangeability more straight forward. Those two moves won’t solve every commercial hurdle, but they materially reduce development burden. Below is a breakdown of the key policy changes, what they mean for different players, and how each region might respond. United States: Simpler files, but access still decid...